Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)
Twitter
Tags: stocks
Stocks: INSY, NBIX, SNY

3 "Cheap" Biotech Stocks to Buy Now for Gains as High as 180%

By Ashley Moore, Associate Editor, Money Morning • July 5, 2017

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

Today we're bringing Money Morning readers three cheap biotech stocks to buy. One of these stocks is projected to gain as much as 180% in the next 12 months alone.

Cheap biotech stocks to buyWhen some investors hear "cheap," they either think "shares under $5" or "low quality." We define these biotech stocks as "cheap" because they are undervalued at their current prices. Their growth potential is very high relative to today's share price. For the reasons we'll show you here, these stocks could have double- and triple-digit gains this year.

This first "cheap" biotech stock to buy has a new drug that just came out in April, along with 13 others currently in phase 3 trials...

Undervalued Biotech Stocks to Buy, No. 3: Sanofi SA

Sanofi SA (ADR) (NYSE: SNY) is one of Money Morning Director of Technology & Venture Capital Research Michael A. Robinson's favorite biotech stocks.

There are two big reasons for his bullish position on Sanofi.

The first is the release of a new drug called Dupixent in April 2017. According to Robinson, this drug is expected to have annual sales of $3 billion by 2020. That would be an 8.2% increase from its 2016 revenue of $36.6 billion.

Dupixent is used to treat eczema, but only for difficult and painful cases. The biggest benefit of this drug is the lack of cancerous side effects that are common in other eczema treatments. This helps protect the drug from direct competition, according to Robinson.

Sign up for SMS so you never miss special events, exclusive offers, and weekly bonus trades.

The second reason Robinson thinks Sanofi is a great biotech stock to buy is its pipeline. The company has 44 drugs in its pipeline with 13 of them in phase 3 trials. According to the FDA, 25% to 30% of drugs that make it to phase 3 trials will make it to the last phase of trials - giving Sanofi a good chance of getting some of its 13 products to market.

So far this year, SNY has gained 19% while the Dow has only gained 7.8%. Currently, it trades for $48.50 a share, and analysts project it could get as high as $54.50 by next year. That's a 12% gain from its current price.

This next stock could gain even more, potentially doubling your money in the next 12 months with a new drug on the market in August...

Undervalued Biotech Stocks to Buy, No. 2: Insys Therapeutics Inc.

Insys Therapeutics Inc. (Nasdaq: INSY) is releasing a new drug, Syndros, in August that could contribute to its stock doubling in price...

Money Morning Executive Editor Bill Patalon sees Syndros at the intersection of two very powerful trends. They are the "war on pain" and the "legalization of medical marijuana."

The war on pain is the push for doctors to find non-opioid pain therapies to treat chronic pain. Almost 60,000 people died from overdosing on opioids in the United States last year.

BREAKING: New Legislation Could Turn Tiny Pot Stocks into Millions. Click Here...

Couple that with a projected pain therapies market worth $83 billion by 2024, and Syndros has huge sales growth potential. In 2015, the pain treatment market was worth $60 billion globally, according to Transparency Market Research.

The second trend is the legalization of medical marijuana. Dronabinol, Syndros' active ingredient, is cannabinoid-based.

"Insys has big upside because it's trying (and, so far, succeeding with flying colors) to work at the 'convergence' of those two powerful trends," said Patalon in May.

The analysts that follow INSY agree. The consensus one-year target is $16.40. Some analysts have a target price of $26.00, which is 99% higher than its current trading price of $13.05.

But these potential gains are small compared to our next stock. It's expected to gain as much as 182% in the next 12 months. Not to mention it's considered a "foundational" stock on which to build your biotech portfolio, according to Money Morning Biotech Investment Specialist Ernie Tremblay...

Join the conversation. Click here to jump to comments…

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments


Latest News

May 30, 2023 • By Chris Johnson

A.I., Oil, and Interest Rates - Oh My

May 30, 2023 • By Shah Gilani

earnings
The Best Way to Play the Tech Stock Boom

May 30, 2023 • By Garrett Baldwin

Momentum Is Negative - Here Are Three Wealth Strategies to Employ Right Away
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Flashpoint Trader Darknet Hyper Momentum Trader Alpha Accelerators Weekly Profit Cycles Brutus Alerts Resource Traders Alliance

Ā© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz